In 2015, Intrexon purchased
Oxitec, a maker of genetically sterile insects, for $160 million. In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the
FDA for a
CAR-T based therapy (investigational drug name PRGN-3006) to treat
acute myeloid leukemia. In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing. With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from
Randal J. Kirk. ==See also==